Vascular stem cells and ischaemic retinopathies

Alan W. Stitt, Christina L. O'Neill, Michelle T. O'Doherty, Desmond B. Archer, Tom A. Gardiner, Reinhold J. Medina

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Retinal ischaemic disorders such as diabetic retinopathy and retinal vein occlusion are common. The hypoxia-related stimuli from oxygen-deprived neural and glial networks can drive expression of growth factors and cytokines which induce leakage from the surviving vasculature and/or pre-retinal and papillary neovascularisation. If left untreated, retinal vascular stasis, hypoxia or ischaemia can lead to macular oedema or fibro-vascular scar formation which are associated with severe visual impairment, and even blindness. Current therapies for ischaemic retinopathies include laser photocoagulation, injection of corticosteroids or VEGF-antibodies and vitreoretinal surgery, however they carry significant side effects. As an alternative approach, we propose that if reparative intra-retinal angiogenesis can be harnessed at the appropriate stage, ischaemia could be contained or reversed. This review provides evidence that reperfusion of ischaemic retina and suppression of sight-threatening sequelae is possible in both experimental and clinical settings. In particular, there is emphasis on the clinical potential for endothelial progenitor cells (EPCs) to promote vascular repair and reversal of ischaemic injury in various tissues including retina. Gathering evidence from an extensive published literature, we outline the molecular and phenotypic nature of EPCs, how they are altered in disease and provide a rationale for harnessing the vascular reparative properties of various cell sub-types. When some of the remaining questions surrounding the clinical use of EPCs are addressed, they may provide an exciting new therapeutic option for treating ischaemic retinopathies. (C) 2011 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)149-166
Number of pages18
JournalProgress in Retinal and Eye Research
Volume30
Issue number3
DOIs
Publication statusPublished - May 2011

Fingerprint

Blood Vessels
Stem Cells
Retina
Ischemia
Vitreoretinal Surgery
Retinal Neovascularization
Retinal Vein Occlusion
Retinal Vessels
Macular Edema
Light Coagulation
Vision Disorders
Diabetic Retinopathy
Blindness
Neuroglia
Vascular Endothelial Growth Factor A
Reperfusion
Cicatrix
Intercellular Signaling Peptides and Proteins
Adrenal Cortex Hormones
Lasers

Cite this

Stitt, Alan W. ; O'Neill, Christina L. ; O'Doherty, Michelle T. ; Archer, Desmond B. ; Gardiner, Tom A. ; Medina, Reinhold J. / Vascular stem cells and ischaemic retinopathies. In: Progress in Retinal and Eye Research. 2011 ; Vol. 30, No. 3. pp. 149-166.
@article{0e12def6f3ff4080a0a6e2c36d1ba82a,
title = "Vascular stem cells and ischaemic retinopathies",
abstract = "Retinal ischaemic disorders such as diabetic retinopathy and retinal vein occlusion are common. The hypoxia-related stimuli from oxygen-deprived neural and glial networks can drive expression of growth factors and cytokines which induce leakage from the surviving vasculature and/or pre-retinal and papillary neovascularisation. If left untreated, retinal vascular stasis, hypoxia or ischaemia can lead to macular oedema or fibro-vascular scar formation which are associated with severe visual impairment, and even blindness. Current therapies for ischaemic retinopathies include laser photocoagulation, injection of corticosteroids or VEGF-antibodies and vitreoretinal surgery, however they carry significant side effects. As an alternative approach, we propose that if reparative intra-retinal angiogenesis can be harnessed at the appropriate stage, ischaemia could be contained or reversed. This review provides evidence that reperfusion of ischaemic retina and suppression of sight-threatening sequelae is possible in both experimental and clinical settings. In particular, there is emphasis on the clinical potential for endothelial progenitor cells (EPCs) to promote vascular repair and reversal of ischaemic injury in various tissues including retina. Gathering evidence from an extensive published literature, we outline the molecular and phenotypic nature of EPCs, how they are altered in disease and provide a rationale for harnessing the vascular reparative properties of various cell sub-types. When some of the remaining questions surrounding the clinical use of EPCs are addressed, they may provide an exciting new therapeutic option for treating ischaemic retinopathies. (C) 2011 Elsevier Ltd. All rights reserved.",
author = "Stitt, {Alan W.} and O'Neill, {Christina L.} and O'Doherty, {Michelle T.} and Archer, {Desmond B.} and Gardiner, {Tom A.} and Medina, {Reinhold J.}",
year = "2011",
month = "5",
doi = "10.1016/j.preteyeres.2011.02.001",
language = "English",
volume = "30",
pages = "149--166",
journal = "Progress in Retinal and Eye Research",
issn = "1350-9462",
publisher = "Elsevier Limited",
number = "3",

}

Vascular stem cells and ischaemic retinopathies. / Stitt, Alan W.; O'Neill, Christina L.; O'Doherty, Michelle T.; Archer, Desmond B.; Gardiner, Tom A.; Medina, Reinhold J.

In: Progress in Retinal and Eye Research, Vol. 30, No. 3, 05.2011, p. 149-166.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vascular stem cells and ischaemic retinopathies

AU - Stitt, Alan W.

AU - O'Neill, Christina L.

AU - O'Doherty, Michelle T.

AU - Archer, Desmond B.

AU - Gardiner, Tom A.

AU - Medina, Reinhold J.

PY - 2011/5

Y1 - 2011/5

N2 - Retinal ischaemic disorders such as diabetic retinopathy and retinal vein occlusion are common. The hypoxia-related stimuli from oxygen-deprived neural and glial networks can drive expression of growth factors and cytokines which induce leakage from the surviving vasculature and/or pre-retinal and papillary neovascularisation. If left untreated, retinal vascular stasis, hypoxia or ischaemia can lead to macular oedema or fibro-vascular scar formation which are associated with severe visual impairment, and even blindness. Current therapies for ischaemic retinopathies include laser photocoagulation, injection of corticosteroids or VEGF-antibodies and vitreoretinal surgery, however they carry significant side effects. As an alternative approach, we propose that if reparative intra-retinal angiogenesis can be harnessed at the appropriate stage, ischaemia could be contained or reversed. This review provides evidence that reperfusion of ischaemic retina and suppression of sight-threatening sequelae is possible in both experimental and clinical settings. In particular, there is emphasis on the clinical potential for endothelial progenitor cells (EPCs) to promote vascular repair and reversal of ischaemic injury in various tissues including retina. Gathering evidence from an extensive published literature, we outline the molecular and phenotypic nature of EPCs, how they are altered in disease and provide a rationale for harnessing the vascular reparative properties of various cell sub-types. When some of the remaining questions surrounding the clinical use of EPCs are addressed, they may provide an exciting new therapeutic option for treating ischaemic retinopathies. (C) 2011 Elsevier Ltd. All rights reserved.

AB - Retinal ischaemic disorders such as diabetic retinopathy and retinal vein occlusion are common. The hypoxia-related stimuli from oxygen-deprived neural and glial networks can drive expression of growth factors and cytokines which induce leakage from the surviving vasculature and/or pre-retinal and papillary neovascularisation. If left untreated, retinal vascular stasis, hypoxia or ischaemia can lead to macular oedema or fibro-vascular scar formation which are associated with severe visual impairment, and even blindness. Current therapies for ischaemic retinopathies include laser photocoagulation, injection of corticosteroids or VEGF-antibodies and vitreoretinal surgery, however they carry significant side effects. As an alternative approach, we propose that if reparative intra-retinal angiogenesis can be harnessed at the appropriate stage, ischaemia could be contained or reversed. This review provides evidence that reperfusion of ischaemic retina and suppression of sight-threatening sequelae is possible in both experimental and clinical settings. In particular, there is emphasis on the clinical potential for endothelial progenitor cells (EPCs) to promote vascular repair and reversal of ischaemic injury in various tissues including retina. Gathering evidence from an extensive published literature, we outline the molecular and phenotypic nature of EPCs, how they are altered in disease and provide a rationale for harnessing the vascular reparative properties of various cell sub-types. When some of the remaining questions surrounding the clinical use of EPCs are addressed, they may provide an exciting new therapeutic option for treating ischaemic retinopathies. (C) 2011 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.preteyeres.2011.02.001

DO - 10.1016/j.preteyeres.2011.02.001

M3 - Article

C2 - 21352947

VL - 30

SP - 149

EP - 166

JO - Progress in Retinal and Eye Research

JF - Progress in Retinal and Eye Research

SN - 1350-9462

IS - 3

ER -